Optimizing Therapy in HR+/HER2-Negative Metastatic Breast Cancer: Navigating Novel Treatments and Personalized Care

Program Description

The landscape of HR+/HER2-negative (HER2−) metastatic breast cancer (mBC) presents a significant burden, especially as patients will inevitably develop endocrine resistance. Understanding the underlying molecular mechanisms and mutations driving this resistance is crucial for guiding treatment selection. Current treatments for HR+/HER2− mBC commonly involve endocrine therapies as the backbone, often combined with targeted therapies such as CDK4/6 inhibitors, selective estrogen receptor degraders, and inhibitors of the PI3K/AKT/PTEN pathway. For patients with BRCA mutations, PARP inhibitors may also be considered. The oncology pharmacist plays a pivotal role in managing these complex treatment regimens. A strong understanding of the pharmacology and appropriate sequencing of these agents is required to support the integration of targeted therapies and molecular profiling strategies, navigate patient selection, leverage clinical evidence, and optimize patient outcomes in a landscape dominated by precision medicine. This session will review the latest clinical trial data for these novel therapies, with faculty experts highlighting clinical considerations and the nuances of mutation-driven therapy to optimize treatment strategies for HR+/HER2− mBC.

Target audience: Oncology pharmacists

Type of activity: Application
Release date: July 25, 2025
Expiration date: July 25, 2026

Time to complete activity: 1.0 hour

Learner level: Intermediate, Advanced
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Examine the complexities of novel therapies for hormone receptor-positive (HR+)/HER2-negative (HER2‒) metastatic breast cancer, including dosing variations, drug interactions, and patient-specific considerations
• Analyze the latest clinical advancements in HR+/HER2‒ metastatic breast cancer and their impact on treatment selection and sequencing
• Design personalized treatment plans for HR+/HER2‒ metastatic breast cancer by integrating patient-specific factors, therapeutic goals, and evidence-based approaches